Astral Systems raises £23m led by Mercia Ventures and Tees River
This article covers Astral Systems, a Bristol-based deep‑tech biotech startup that has raised £23m in a first close of a series A funding round led by Mercia Ventures to accelerate production of its modular Multi-State Fusion reactors and commercialise medical radioisotopes. The funding will finance reactor scale-up at a new facility, advance isotope production towards early 2027 and expand Astral's team, targeting domestic production of medical radioisotopes used in cancer diagnostics and therapies.
Astral Systems has raised £23 million in a first close of a series A funding round led by Mercia Ventures to accelerate production of its modular Multi-State Fusion (MSF) reactors and commercialise medical radioisotopes. The Bristol-based deep-tech, biotech startup says the capital will finance reactor scale-up at a new facility on the former Berkeley Power Station, push isotope production towards early 2027, and expand a team that currently numbers 23.
Why it matters
Global supply chains for medical radioisotopes are fragile, yet more than 50 million nuclear medicine procedures take place each year. Shortages can directly affect cancer diagnosis and targeted therapies. Astral’s proposition is notable because it targets a nearer-term commercial application of fusion technology rather than distant grid-scale power generation: producing isotopes such as Actinium-225 and Lead-212 that are used in emerging cancer treatments.
Inside the product
Astral’s core hardware is its Multi-State Fusion reactor, which the company describes as a compact, modular design capable of continuous neutron production. Astral says it already operates multiple reactors at Technology Readiness Level 9 and has three commercial fusion facilities that have generated more than £3 million in revenue from research contracts.
The company is working with McMaster University in Canada and the Institute for Energy and Nuclear Research (IPEN) in Brazil on producing Actinium-225 and Lead-212. Astral has also partnered with the University of Bristol on over a year of tritium breeder blanket research and recently secured a UK grant to explore its tech as a testbed for advanced fission fuels. The immediate product roadmap aims to run several next-generation compact fusion reactors at full capacity by the end of 2026 and to establish what Astral calls a high-flux, continuously operable private fusion volumetric neutron source.
### Who's backing the round
Who are the investors?
The series A first close was led by Mercia Ventures, with participation from Tees River, Daphni, Blast Club, Speedinvest, and Playfair. This injection of £23 million takes Astral’s total raised to more than £28 million.
Investors pointed to the company’s near-term revenue from research contracts, operational reactors, and the potential to address a clear market need for medical isotopes. Astral’s stated plan to scale manufacturing of modular reactors and to move towards profitability in 2027 framed the commercial case for the round.
In the announcement, Lee Lindley, Investor at Mercia Ventures, said:
We're incredibly proud to have led this investment into Astral Systems and are excited about working with Talmon and Tom. Astral's technology has the potential to transform the manufacturing and supply of medical isotopes, which are vitally important for diagnostic and therapeutic purposes. Astral Systems is a perfect example of the bold ideas that Mercia likes to back.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
In the announcement, Talmon Firestone, Co-founder & CEO at Astral Systems, said:
We are rewriting how we approach fusion and, in doing so, redefining what it means to be a fusion company. This is evident in our novel technology and its near-term applications in modern medicine, as well as facilitating the search for hybrid energy. With this new funding we can accelerate our ambition of building a profitable, impactful fusion business, and build on the momentum of the past 12 months with the backing of our investors.
Astral has recently appointed NASA Laureate and nuclear physicist Dr Theresa Benyo as Chief Research Officer and named Dr Mahmoud Bakr as Chief Scientist, moves the company says strengthen its scientific leadership as it scales.
The bigger picture
Astral’s fundraising highlights a trend of startups pursuing practical, revenue-generating applications of fusion outside the traditional focus on electricity generation. Producing medical isotopes domestically could reduce reliance on complex international supply chains and provide a commercial pathway for fusion-derived neutron sources.
For the UK ecosystem, the deal reinforces interest in converging biotech and deep-tech capabilities — from university partnerships to factory-scale manufacturing — and it aligns with government and research priorities around medical technologies and advanced nuclear research. If Astral meets its targets for capacity, revenue, and job growth, it would be one of the more concrete demonstrations to date of fusion technologies delivering targeted, near-term societal value.
They've invested in Astral Systems
Get to know these biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Mercia( ) Mercia is a venture capital firm focused on fuelling UK business ambitions throu... Manchester  | ||||
 Daphni( ) The venture capital firm is a mission-driven B Corp investing in European early-... Paris, France  | ||||
 Blast Club( ) | ||||
 | ||||
 Playfair Capital( ) The venture capital firm focuses on providing an unfair advantage to founders, s... London | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK